Brought to you by 
EA Pharma gets preclinical mAb from Calypso Biotech
03 Apr 2017
Executive Summary
Calypso Biotech SA licensed Eisai's EA Pharma Co. Ltd. exclusive worldwide rights to develop, manufacture, and market its matrix metalloproteinase 9 (MMP-9) inhibitor CALY00.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com